A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis
- 466 Downloads
Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal adenocarcinoma.
A single patient with esophageal adenocarcinoma and on peritoneal dialysis for end-stage renal disease was treated with cisplatin 25 mg/m2 on day 1 of weeks 1 and 5 and continuous infusional 5-fluorouracil 1000 mg/m2/day on days 1–4 of weeks 1 and 5 along with daily radiation therapy. Intense plasma and dialysate sampling was performed during the week 5 administration, followed by quantitation of platinum by atomic absorption spectrophotometry and 5-fluorouracil by LC–MS/MS.
Following systemic administration, clearance of ultrafilterable (active) platinum over the first 6 h was 20.8 L/h, which is lower than previously reported clearance levels of ultrafilterable platinum. Total platinum AUC was 131 μg h/mL, also higher than an AUC previously reported for total platinum in patients with normal renal function. Platinum-related material was detected in the peritoneal cavity, but this is likely inactive. 5-Fluorouracil penetrated the intraperitoneal cavity, but the contribution of peritoneal dialysis to drug clearance was negligible at 0.072 %.
Administration of intravenous cisplatin and 5-fluorouracil chemotherapy to a patient treated with continuous ambulatory peritoneal dialysis is feasible, but clearance in dialysate is nominal, thus suggesting that dose reduction is indicated for cisplatin. Systemic drug administration results in limited intraperitoneal penetration of 5-fluorouracil and inactive platinum species.
KeywordsCisplatin 5-Fluorouracil Pharmacokinetics Peritoneal dialysis
This project was supported by the Case Comprehensive Cancer Center (P30CA043703), Case Western Reserve University Clinical and Translational Science Collaborative (UL1TR000439) and the University of Pittsburgh Cancer Institute Cancer Pharmacokinetics and Pharmacodynamics Facility (P30CA047904). Dr. Eads is a recipient of a K12 Paul Calabresi Scholar Award (2K12CA076917-17).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ (2003) A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 14:1783–1790CrossRefPubMedGoogle Scholar
- 3.Okuyama M, Motoyama S, Maruyama K, Ohta H, Tsuchiya N, Oyake J, Ogawa J (2005) Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug. Gan To Kagaku Ryoho 32:1029–1032PubMedGoogle Scholar
- 7.Arai Y, Oyama T, Hotta K, Tomori A, Miyata Y (2008) Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60 Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis. Nihon Shokakibyo Gakkai Zasshi 105:1482–1488PubMedGoogle Scholar
- 10.Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623–1627CrossRefPubMedGoogle Scholar
- 11.National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology, esophageal and esophagogastric junction cancers version 3. 2015. http://www.nccn.org. Accessed 21 Sept 2015
- 13.Colville H, Dzadony R, Kemp R, Stewart S, Zeh HJ 3rd, Bartlett DL, Holleran J, Schombert K, Kosovec JE, Egorin MJ, Beumer JH (2010) In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corpor Technol 42:75–79PubMedCentralPubMedGoogle Scholar
- 15.Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955CrossRefPubMedGoogle Scholar
- 16.Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007PubMedGoogle Scholar
- 19.Ikeda K, Terashima M, Kawamura H, Takiyama I, Koeda K, Takagane A, Sato N, Ishida K, Iwaya T, Maesawa C, Yoshinari H, Saito K (1998) Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 28:168–175CrossRefPubMedGoogle Scholar